---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-067432"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:45:08.330575+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma FY2023: JELMYTO revenue $82.7M (+28% YoY), net loss narrows, UGN-102 NDA on track

## Summary
- Full year JELMYTO net revenue $82.7M, up ~28% YoY from $64.4M; Q4 revenue $23.5M (+30% YoY).
- Net loss narrowed to $102.2M ($3.55/share) for FY2023 from $109.8M ($4.81/share) in 2022.
- Rolling NDA for UGN-102 initiated Jan 2024; completion target Sep 2024, potential FDA decision Q1 2025.
- Licensed next-gen mitomycin formulations (UGN-103/104) from medac with IP protection until Dec 2041.
- Restructured Pharmakon loan: lower interest rate, deferred payback, up to $100M additional credit facility.

## SEC filing metadata
- accession: 0001193125-24-067432
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/0001193125-24-067432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/d675566d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-067432
- JSON: https://secwatch.observer/filing/0001193125-24-067432.json
- Plain text: https://secwatch.observer/filing/0001193125-24-067432.txt

## Key facts
- Earnings Releases
  UroGen Pharma Ltd. reported the fourth quarter of 2023 results: revenue $23.5 million.
  - Period: the fourth quarter of 2023
  - Revenue: $23.5 million
  - Result: reported results
  source text: UroGen reported JELMYTO net product revenues of $23.5 million in the fourth quarter of 2023, compared to $18.1 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/0001193125-24-067432-index.htm
- Earnings Releases
  UroGen Pharma Ltd. reported the full year 2023 results: revenue $82.7 million.
  - Period: the full year 2023
  - Revenue: $82.7 million
  - Result: reported results
  source text: Net JELMYTO product revenue for the full year 2023 was $82.7 million, compared to $64.4 million in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/0001193125-24-067432-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.